REVLIMID (lenalidomide) is today listed on the Pharmaceutical Benefits Scheme (PBS) for newly diagnosed multiple myeloma patients ineligible for transplant.
Multiple myeloma is a blood cancer that develops from plasma cells in the bone marrow.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Feb 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Feb 17